| Name | SCH-336 |
| Description | SCH-336 is a CB2 receptor agonist (Ki-1.8 nM, EC50-2 nM) with effective, selective, and oral activity. SCH-336 is also bioactive against CB1 receptor, and is 100 times more selective to CB2 receptor than CB1. SCH-336 reduced the binding of guanosine 5' -3-o -(sulfur) triphosphate to the membrane containing hCB, inhibited BaF3/CB2 cell migration, inhibited leukocyte migration in mouse delayed hypersensitivity models, and inhibited antigen-induced pulmonary eosinophilia in mouse allergy models. |
| In vitro | SCH 336 (also known as Sch.336) exhibits competitive binding with [3H]CP55,940 to human CB2 receptors on Sf9 cell membranes, with a Ki value of 1.8 nM. It reduces GTPγS binding on membranes containing human CB2 receptors, with an EC50 of 2 nM. However, its potency decreases on membranes containing CB1 receptors, with an EC50 of 200 nM [1]. Moreover, SCH 336 inhibits the migration of BaF3/CB2 cells towards 100 nM 2-AG, with an IC50 of 34 nM [1]. |
| In vivo | In in vivo studies, when administered intraperitoneally (i.p.) at doses of 0.02-2.0 mg/kg, SCH 336 significantly inhibits leukocyte migration [1]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 90 mg/mL (166.78 mM), Sonication is recommended.
|
| Keywords | SCH-336 | SCH-225336 | CB2 | CannabinoidReceptor | Cannabinoid Receptor |
| Inhibitors Related | RTICBM-189 | β-Caryophyllene | CB2 modulator 1 | Pregnenolone | Pregnenolone acetate | CB1 antagonist 2 | Dehydroabiethylamine | CB2 receptor agonist 2 | AM-1235 | 2,3-Butanediol | Drinabant | AM281 |
| Related Compound Libraries | Bioactive Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Multi-Target Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max | GPCR Compound Library | Anti-Cancer Compound Library |
United States
